A comprehensive evaluation of the clinical and cost effectiveness of a new (single) health technology (single therapy for single application); presented by a drug sponsor after achieving marketing authorisation – for the consideration by a national health agency of whether the costs and benefits of the new treatment warrant its adoption by a national health system programme.
Menu